Q1 2012 results (NewLink Genetics) - May 22, 2012 - Anticipated clinical data for P2 dose finding study in pancreatic cancer at both the 53rd Annual Meeting of the American Gastroenterological Association in conjunction with Digestive Disease Week on May 22, 2012 and the ASCO annual meeting on June 4, 2012.
Anticipated data • Anticipated P3 trial results • Pancreatic Cancer
|
|
HyperAcute Pancreas Vaccine
----
2012 Key Accomplishments to Date
Continued to advance our HyperAcute Pancreas Phase 3 clinical trial. Enrollment is matching our anticipated levels and we continue to expect to complete enrollment before the end of 2013. We still expect that our first interval look will occur at the end of 2012 or early 2013. Data from the HyperAcute Pancreas Phase 2 clinical trial will be presented at both the 53rd Annual Meeting of the American Gastroenterological Association in conjunction with Digestive Disease Week (DDW) on May 22, 2012 and the 2012 American Society of Clinical Oncology (ASCO) Annual meeting on June 4, 2012.
---
|